logo
Plus   Neg
Share
Email

Zynerba Pharma: Zygel Study Fails To Achieve Statistical Significance In Endpoints

Zynerba Pharmaceuticals, Inc. (ZYNE) reported top line results from the 14-week pivotal CONNECT-FX (clinical study of Cannabidiol in Children and Adolescents with Fragile X) trial. The trial assessed the efficacy and safety of Zygel CBD gel as a treatment in for behavioral symptoms of Fragile X syndrome in 212 patients. Zygel did not achieve statistical significance versus placebo in the primary endpoint of improvement in the Social Avoidance subscale of the Aberrant Behavior Checklist. Zygel also did not show statistical significance versus placebo in the three key secondary endpoints.

Based on the analysis, Zynerba intends to meet with the FDA regarding a regulatory path forward for Zygel.

Shares of Zynerba Pharma were down nearly 40% in pre-market trade on Tuesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
RELATED NEWS
Follow RTT